WIXOM, Mich., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that the last patient has completed the Phase IIb clinical study to investigate Soluble Ferric Pyrophosphate (SFP), the Company's proprietary investigational iron maintenance therapy.
